NEW YORK (AP) — Teva Pharmaceutical Industries Ltd.'s fourth-quarter profit sank 34 percent as an acquisition by the world's largest generic drugmaker improved revenue but raised expenses.
The Israeli company said Wednesday its net income dropped to $506 million, or 57 cents per share, in the three months that ended Dec. 31. That compares to $771 million, or 85 cents per share, in the last quarter of 2010.
Excluding a variety of one-time items, like acquisition, amortization and impairment charges, Teva earned $1.59 per share.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
